# DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Study · id `cardio:ct-nct02110303` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02110303](<https://clinicaltrials.gov/study/NCT02110303>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02110303

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

## Technical summary

Registry record NCT02110303. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2017-05-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 220 participants (enrolled count; ClinicalTrials.gov record NCT02110303, source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)
- Start date: 2015-03 (registry gives no type) (ClinicalTrials.gov record NCT02110303, source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)
- Primary completion: 2017-05-26 (actual) (ClinicalTrials.gov record NCT02110303, source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)
- Completion: 2018-04 (actual) (ClinicalTrials.gov record NCT02110303, source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02110303, source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02110303-2025-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
- Acronym: DIAMOND
- Condition: Coronary Artery Disease
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Placebo
- Lead sponsor: University of Edinburgh
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Edinburgh (`cardio:org-university-of-edinburgh`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque (`cardio:pubmed-31422134`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Coronary 18F-Fluoride Uptake and Progression of Coronary Artery Calcification (`cardio:pubmed-33297761`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a2687fe9421d9129fdc360e2b747f68e4e898bc83a34037fd397daf5cf6ac28d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
